263 related articles for article (PubMed ID: 20107799)
1. Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.
Lam ET; Au JL; Otterson GA; Guillaume Wientjes M; Chen L; Shen T; Wei Y; Li X; Bekaii-Saab T; Murgo AJ; Jensen RR; Grever M; Villalona-Calero MA
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1019-29. PubMed ID: 20107799
[TBL] [Abstract][Full Text] [Related]
2. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Billings FT; Bradof JE; Baker M; Greco FA
Cancer; 2001 Nov; 92(9):2391-8. PubMed ID: 11745295
[TBL] [Abstract][Full Text] [Related]
3. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
[TBL] [Abstract][Full Text] [Related]
5. A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer.
Grossi F; de Marinis F; Gebbia V; Riccardi F; Caffo O; Gamucci T; Ferraù F; Nardi M; Moscetti L; Boni L; Dondi D; Galligioni E
Cancer Chemother Pharmacol; 2012 Feb; 69(2):369-75. PubMed ID: 21833588
[TBL] [Abstract][Full Text] [Related]
6. A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer.
Matsui K; Hirashima T; Nitta T; Kobayashi M; Ogata Y; Furukawa M; Kudoh S; Yoshimura N; Mukohara T; Yamauchi S; Shiraishi S; Kamoi H; Negoro S; Takeda K; Nakagawa K; Takada M; Yana T; Fukuoka M
Jpn J Clin Oncol; 2005 Apr; 35(4):181-7. PubMed ID: 15845566
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies.
Spiridonidis CH; Laufman LR; Jones J; Rhodes VA; Wallace K; Nicol S
J Clin Oncol; 1998 Dec; 16(12):3866-73. PubMed ID: 9850032
[TBL] [Abstract][Full Text] [Related]
8. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.
Rebattu P; Quantin X; Ardiet C; Morere JF; Azarian MR; Schuller-Lebeau MP; Pujol JL
Lung Cancer; 2001; 33(2-3):277-87. PubMed ID: 11551423
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
[TBL] [Abstract][Full Text] [Related]
10. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study.
Kouroussis C; Mavroudis D; Kakolyris S; Voloudaki A; Kalbakis K; Souglakos J; Agelaki S; Malas K; Bozionelou V; Georgoulias V
Lung Cancer; 2004 Jun; 44(3):363-8. PubMed ID: 15140550
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma.
Popa IE; Stewart K; Smith FP; Rizvi NA
Cancer; 2002 Oct; 95(8):1714-9. PubMed ID: 12365019
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study.
Casal J; Amenedo M; Mel JR; Antón LM; Rodríguez-López R; López-López R; González-Ageitos A; Castellanos J; Constenla M; Tisaire JL
Cancer Chemother Pharmacol; 2007 Oct; 60(5):725-32. PubMed ID: 17273825
[TBL] [Abstract][Full Text] [Related]
13. Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status: results of a Minnie Pearl Cancer Research Network phase II trial.
Hainsworth JD; Erland JB; Barton JH; Thompson DS; Stagg MP; Bradof JE; Twele TW; Greco EA;
Clin Lung Cancer; 2003 Jul; 5(1):33-8. PubMed ID: 14596701
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC).
Israel V; Tagawa ST; Snyder T; Jeffers S; Raghavan D
Invest New Drugs; 2004 Aug; 22(3):291-7. PubMed ID: 15122076
[TBL] [Abstract][Full Text] [Related]
16. Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer: a phase II study.
Syrigos KN; Karapanagiotou E; Charpidou A; Dilana K; Dannos I; Dionellis G; Rigopoulou A; Georgatou N; Roussos C
J Chemother; 2007 Aug; 19(4):438-43. PubMed ID: 17855189
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma.
Gajra A; Mehdi SA; Kirshner J; Newman N; Graziano SL
Lung Cancer; 2001 May; 32(2):189-96. PubMed ID: 11325490
[TBL] [Abstract][Full Text] [Related]
18. Influence of altering administration sequence of docetaxel, gemcitabine and cisplatin in patients with advanced non-small cell lung cancer.
Harita S; Watanabe Y; Kiura K; Tabata M; Takigawa N; Kuyama S; Kozuki T; Kamei H; Tada A; Okimoto N; Genba K; Tada S; Ueoka H; Hiraki S; Tanimoto M
Anticancer Res; 2006; 26(2B):1637-41. PubMed ID: 16619585
[TBL] [Abstract][Full Text] [Related]
19. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial.
Georgoulias V; Ardavanis A; Tsiafaki X; Agelidou A; Mixalopoulou P; Anagnostopoulou O; Ziotopoulos P; Toubis M; Syrigos K; Samaras N; Polyzos A; Christou A; Kakolyris S; Kouroussis C; Androulakis N; Samonis G; Chatzidaki D
J Clin Oncol; 2005 May; 23(13):2937-45. PubMed ID: 15728228
[TBL] [Abstract][Full Text] [Related]
20. Biweekly administration of docetaxel and gemcitabine as adjuvant therapy for stage II and IIIA non-small cell lung cancer: a phase II study.
Syrigos KN; Konstantinou M; Sepsas E; Papamichales G; Loullias A; Belenis I; Skottis I; Charpidou A; Roussos C
Anticancer Res; 2007; 27(4C):2887-92. PubMed ID: 17695466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
